RapidQ is simply the new name for NRL’s trusted Point-of-Care Testing (PoCT) service. While we have changed our name and program offering,  the same high-quality testing, reliability, and support you’ve come to expect remain unchanged.

In collaboration with the World Health Organization (WHO), NRL has identified the following barriers to implementing effective QA for PoCT—and has developed targeted solutions to overcome them:

1. Sample Type Limitations

Most PoCT serology tests use capillary whole blood or oral fluid. Traditional QA samples often use serum or plasma, failing to account for the pre-analytical challenges of PoCT—commonly the highest point of error.

2. Single-Use Devices

PoCT devices are typically single-use, meaning QA can only assess individual cartridges. This does not account for variability across different cartridges or batches.

3. Informal Testing Environments

Testing often occurs in community clinics or non-clinical settings by personnel without formal laboratory training. Testing may be sporadic due to stockouts or program-based scheduling.

4. Fragmented Kit Access

In many low- and middle-income countries, access to PoCT kits can be inconsistent due to funding constraints, distribution issues, or project-based implementation that doesn’t align with traditional EQA timelines.

5. Remote and Harsh Settings

PoCT is widely used in rural and remote areas, including services for First Peoples. These areas may face extreme temperatures, difficult logistics, and limited infrastructure such as electricity or refrigeration.

6. Costly Shipping and Storage

Shipping QA materials under UN3373 regulations, especially with dry ice, is often prohibitively expensive. Many PoCT sites lack appropriate cold storage facilities for infectious disease QA materials.

7. Inflexible Test Schedules

Fixed EQA test events can be difficult to meet due to shipping delays or import challenges, often leading to missed opportunities and wasted resources.

8. Regulatory Constraints

QA materials are considered in-vitro diagnostic (IVD) devices, making them costly and limiting the development of in-house alternatives.

9. Qualitative Data Challenges

Many PoCT results are qualitative, while most QA programs are built for quantitative results. However, using samples near the detection limit and structured result collection can still provide meaningful data for ongoing test performance monitoring.

10. Data Loss

QA data is often not systematically recorded or followed up. This reduces its effectiveness for post-market surveillance and quality improvement.

11. Stakeholder Misalignment

There’s often a disconnect between QA providers, IVD manufacturers, and major funders. Some manufacturers resist QA oversight, and global funding bodies may enforce minimal QA requirements despite significant investment in diagnostics.

To address common challenges in diagnostic testing, NRL has developed a comprehensive and fit-for-purpose QA program for PoCT, covering a wide range of infectious disease analytes. The program is scientifically validated, scalable, and adaptable to local needs.

• Includes synthetic whole blood for serology and dried tube/swab samples for molecular testing

• Validated for stability at ambient shipping conditions and 4–8°C storage

• Homogeneity and stability independently verified

1. Competency Panels

• One known positive and one known negative sample per analyte

• Used to train testers, verify competence, and monitor reagent batch quality

• Recommended frequency: weekly for active sites, monthly for low-volume sites

2. External Quality Assessment Schemes (EQAS)

• Typically four unknown samples per panel with diverse genotypes, concentrations, and results

• Suggested frequency: 3 times per year, minimum once annually

• Samples manufactured in bulk to keep costs low

• Non-infectious and ambient-stable, reducing shipping costs

• Designed for implementation even in resource-limited settings

NRL collaborates with test kit manufacturers and central procurement agencies to distribute QA materials alongside test reagents—streamlining logistics and reducing overhead.

Unlike traditional fixed-event programs, NRL offers on-demand EQA—allowing facilities to test when ready, avoiding missed windows and reducing the risk of result collusion.

Every panel is equipped with a QR code. Testers scan with a smartphone, complete a bespoke online form, and submit results for real-time analysis and feedback via NRL’s mobile QA portal.